Large Benign Thyroid Tumor Suspected of Anaplastic Thyroid Carcinoma.

We previously reported that upregulation of mortalin (HSPA9/GRP75), the mitochondrial HSP70 chaperone, facilitates tumor cell proliferation and survival in human medullary thyroid carcinoma (MTC), proposing mortalin as a novel therapeutic target for MTC. In this report, we show that mortalin is also upregulated in other thyroid tumor types, including papillary thyroid carcinoma (PTC), follicular thyroid carcinoma (FTC), and anaplastic thyroid carcinoma (ATC), and that mortalin depletion can effectively induce growth arrest and cell death in human PTC (TPC-1), FTC (FTC133), and ATC (8505C and C643) cells in culture. Intriguingly, mortalin depletion induced varied effects on cell cycle arrest (G0/G1 phase arrest in TPC-1 and C643, G2/M phase arrest in 8505C, and mild G2/M phase arrest with increased sub-G0/G1 population in FTC133) and on the levels of TP53, E2F-1, p21CIP1, p27KIP1, and poly (ADP-ribose) polymerase cleavage in these cells, suggesting that thyroid tumor cells respond to mortalin depletion in a cell type-specific manner. In these cells, we also determined the efficacy of triphenyl-phosphonium-carboxy-proxyl (Mito-CP) because this mitochondria-targeted metabolism interfering agent exhibited similar tumor suppressive effects as mortalin depletion in MTC cells. Indeed, Mito-CP also induced robust caspase-dependent apoptosis in PTC and ATC cell lines in vitro, exhibiting IC50 lower than PLX4032 in 8505C cells and IC50 lower than vandetanib and cabozantinib in TPC-1 cells. Intriguingly, Mito-CP-induced cell death was partially rescued by mortalin overexpression, suggesting that Mito-CP may inactivate a mechanism that requires mortalin function. These findings support the significance of mortalin and mitochondrial activity in a broad spectrum of thyroid cancer.

Download Full-text

Uncommon Site of Metastasis and Prolonged Survival in Patients with Anaplastic Thyroid Carcinoma: A Systematic Review of the Literature

Cancers ◽

10.3390/cancers12092585 ◽

2020 ◽

Vol 12 (9) ◽

pp. 2585

Author(s):

Aurora Mirabile ◽

Matteo Biafora ◽

Leone Giordano ◽

Gianluigi Arrigoni ◽

Maria Giulia Cangi ◽

...

Keyword(s):

Systematic Review ◽

Overall Survival ◽

Prognostic Factors ◽

Thyroid Carcinoma ◽

Thyroid Tumor ◽

Anaplastic Thyroid Carcinoma ◽

Review Of The Literature ◽

Malignant Thyroid Tumor ◽

One Year

Anaplastic thyroid carcinoma (ATC) is a very rare, highly aggressive malignant thyroid tumor with an overall survival from 3 to 5 months in most of the cases. Even the modern and intensive treatments seem not to be enough to provide a cure, also for the resectable ones, and the role of chemotherapy is still unclear but does not seem to prolong survival. Nevertheless, some patients survive longer and have a better outcome, even in the presence of metastasis, than what the literature reports. We present the case of a 64-year-old female affected by ATC, treated on February 2018 with surgery followed by chemoradiation. One year after surgery, the patient developed a subcutaneous recurrence that was radically resected and is still alive 29 months after the diagnosis. We propose a systematic review of the literature to deepen the knowledge of the prognostic factors of ATC with the aim to recognize and select the patients with a better outcome, even if metastatic, and to describe a very uncommon site of metastatization.

Download Full-text

Application of Straight Line Tunnel With Less Subcutaneous Separation in Transthoracic Endoscopic Thyroidectomy

International Surgery ◽

10.9738/intsurg-d-16-00037.1 ◽

2017 ◽

Vol 102 (7-8) ◽

pp. 351-355

Author(s):

XiWei Zhang ◽

Gang Liu ◽

Hao Zhang ◽

XueFeng Tang ◽

JianPing Huang

Keyword(s):

Thyroid Carcinoma ◽

Skin Flap ◽

Endoscopic Thyroidectomy ◽

Operation Time ◽

Nodular Goiter ◽

Thyroid Tumor ◽

Anaplastic Thyroid Carcinoma ◽

Straight Line ◽

Partial Thyroidectomy

The objective of this paper was to evaluate the value of straight-line tunnel application in transthoracic endoscopic thyroidectomy. Forty patients were given 3-port transthoracic endoscopic thyroidectomy from March 2011 to June 2014. Preoperative diagnoses found 20 cases of nodular goiter, 16 cases of adenoma, and 4 cases of thyroid calcification. We used a metal rod to free skin flap in a straight way toward the neck, and a straight-line tunnel was created to obtain a good view. All 40 cases involving endoscopic thyroidectomy were performed successfully, 28 were performed with unilateral subtotal thyroidectomy, 5 were performed with unilateral thyroidectomy, 5 were performed with bilateral partial thyroidectomy, and 2 were performed with radical thyroidectomy for carcinoma. One is anaplastic thyroid carcinoma (ATC) and the other is follicular thyroid carcinoma. Operation time was 78.5 ± 18.6 minutes, intraoperative blood loss was 40.2 ± 15.6 mL, intraoperative flap-freeing time was 14.3 ± 3.8 minutes, and the diameter of the thyroid tumor was 3.8 ± 2.5 cm. Postoperative hospital stay was 3.5 ± 2.0 days. One patient got voice hoarseness and recovered in 3 months. Two patients suffered from transient hypocalcemia and recovered without treatment. No subcutaneous effusion or seroma was observed. No recurrence was found during the 12- to 36-month (mean: 28 months) follow-up. One patient felt chest numbness 3 months after the surgery. Thirty-two patients were very satisfied with the cosmetic appearance and 8 patients were satisfied. The application of straight-line tunnel in transthoracic endoscopic thyroidectomy is a simple, safe, feasible procedure with less trauma, seroma, and skin contraction.

Download Full-text